SELECT PUBLICATIONS

Citron ML et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21(8):1431-9. Abstract

Holmes FA et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: A multicenter dose-finding study in women with breast cancer. Ann Oncol 2002a;13(6):903-9. Abstract

Holmes FA et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002b;20(3):727-31. Abstract

Hurria A et al. A prospective longitudinal study of the impact of adjuvant chemotherapy for breast cancer (BC) on older patients functional status and quality of life. San Antonio Breast Cancer Symposium 2005;Abstract 6071.

Kuderer NM et al. Meta-analysis of prophylactic granulocyte colony-stimulating factor (G-CSF) in cancer patients receiving chemotherapy. Proc ASCO 2005;Abstract 8117.

Lyman GH et al. A risk model for first cycle febrile neutropenia in cancer patients receiving systemic chemotherapy. Proc ASCO 2005a;Abstract 8122.

Lyman GH et al. A prospective risk model for neutropenic complications in early-stage breast cancer patients receiving adjuvant chemotherapy. San Antonio Breast Cancer Symposium 2005b;Abstract 3006.

Martin M et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352(22):2302-13. Abstract

Meza LA et al. Filgrastim-mediated neutrophil recovery in patients with breast cancer treated with docetaxel and doxorubicin. Pharmacotherapy 2003;23(11):1424-31. Abstract

Miller KD et al. E2100: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presentation. ASCO 2005a. No abstract available

Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). San Antonio Breast Cancer Symposium 2005b;Abstract 3.

Ozer H et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol 2000;18(20):3558-85. No abstract available

Siena S et al. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily filgrastim in patients with stage II-IV breast cancer. Oncol Rep 2003;10(3):715-24. Abstract

Vogel CL et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23(6):1178-84. Abstract

Winer EP et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status Report 2004. J Clin Oncol 2005;23(3):619-29. Abstract